Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Resources

PER Pulse™ Recaps highlight key elements of the Community Practice Connections™: Advancing RCC: A Focused Assessment of Recent Paradigm Shifts and Next Steps to Move the Field Forward online CME activity.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Eisai Inc., Exelixis, and Prometheus Laboratories Inc.

Community Practice Connections™: Advancing RCC: A Focused Assessment of Recent Paradigm Shifts and Next Steps to Move the Field Forward

Release Date: May 30, 2017
Expiration Date: May 30, 2018
Media: Internet - based

 

Activity Overview

Community Practice Connections™: Advancing RCC: A Focused Assessment of Recent Paradigm Shifts and Next Steps to Move the Field Forward features case-based discussions about standard and emerging therapies for renal cell carcinoma (RCC). Interactive clinical vignettes are followed by brief video interviews with leading experts and short summaries of clinical data related to these clinical settings. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting by physicians who treat patients with RCC.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Eisai Inc., Exelixis, and Prometheus Laboratories Inc.

CME Activity Table of Contents

  • Targeted Therapy in the Adjuvant and Relapsed Metastatic Settings
    Robert Figlin, MD
  • Immunotherapy in RCC in 2017
    David McDermott, MD
  • Informed Therapeutic Sequencing
    Sumanta K. Pal, MD
  • Non‒Clear Cell RCC
    Bernard Escudier, MD
  • Looking Ahead in RCC
    Toni Choueiri, MD

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward oncologists, nurses, and pharmacists. Participants will be primarily those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the management of RCC.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Discuss the biology of RCC and clinical circumstances that inform switching and sequencing of therapies in the care of patients with these malignancies
  • Assess targeted approaches for RCC management, the mechanistic rationale for treatment combinations, and emerging evidence concerning these strategies
  • Describe the role of immunotherapy in the setting of RCC in the context of trial data, real-world experience, and monitoring
  • Apply best practices to manage treatment-related toxicities and assess their impact on clinical decision making to optimize sequencing in the management of RCC
  • Evaluate clinical scenarios that may soon impact the RCC treatment landscape, including evolving compounds, combinations, and biomarkers

Faculty, Staff, and Planners' Disclosures

Program Chair

Toni Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Department of Medical Oncology
Dana-Farber Cancer Institute/Brigham and Women's Hospital
The Jerome and Nancy Kohlberg Endowed Chair
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Disclosure: Grant/Research Support: Pfizer, GlaxoSmithKline, Novartis, Bristol-Myers Squibb, Merck, Exelixis, Roche, AstraZeneca, Tracon, Peloton, Celldex; Consultant: Pfizer, GlaxoSmithKline, Novartis, Bayer, Eisai, Bristol-Myers Squibb, Merck, Roche, Prometheus Laboratories Inc.

Faculty

Bernard Escudier, MD
Chair, Genitourinary Oncology Committee
Gustave Roussy Institute
Paris, France
 
 

Disclosure: Consultant: Pfizer, Novartis, Bristol-Myers Squibb, Roche, Exelixis, Ipsen

Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences Director
Division of Hematology Oncology
Deputy Director Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Disclosure: No relevant financial relationships to disclose.

David F. McDermott, MD
Leader, Dana-Farber Harvard Cancer Center
Kidney Cancer Program Director
Biologic Therapy and Cutaneous Oncology Programs
Beth Israel Deaconess Medical Center Associate Professor of Medicine
Harvard Medical School
Boston Massachusetts

Disclosure: Grant/Research Support: Prometheus Laboratories; Consultant: Bristol-Myers Squibb, Pfizer, Merck, Novartis, Eisai, Exelixis, Array BioPharm, Genentech

Sumanta Kumar Pal, MD
Assistant Clinical Professor
Department of Medical Oncology & Therapeutics Research
Co-director, Kidney Cancer Program
City of hope
Duarte, California

Disclosure: Consultant: Novartis, Pfizer, Astellas, Genentech, GlaxoSmithKline, Bristol-Myers Squibb, Exelisis; Speaker's Bureau: Genentech

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

PER Pulse™ Recap


1 of 3
PER Pulse™ Recap

Community Practice Connections™: Advancing RCC: A Focused Assessment of Recent Paradigm Shifts and Next Steps to Move the Field Forward is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in February 2017 in Orlando, FL. In this online activity, expert faculty discuss standards of care and emerging strategies for renal cell carcinoma (RCC). It features commentary on:

  • Targeted therapy in the adjuvant and relapsed metastatic settings by Robert Figlin, MD
  • Immunotherapy for RCC in 2017 by David McDermott, MD
  • Informed therapeutic sequencing by Sumanta Pal, MD
  • Non‒clear cell RCC by Bernard Escudier, MD
  • A look ahead in RCC, by Toni Choueiri, MD

This first of 1 PER Pulse™ Recaps summarizing the online program focuses on Dr. Figlin’s answers to questions about adjuvant targeted therapy for RCC, during which he discussed:

  • His approach toward a 65-year-old male who underwent partial nephrectomy for a pT3b, Fuhrman grade 3 RCC tumor and who has good performance status
  • Rationale for early treatment of micrometastatic disease in RCC and unanswered questions regarding use of adjuvant therapy
  • The importance of making the best decision with the options available to you at each step of decision making
  • The future of adjuvant therapy (eg, investigations of immunotherapeutics)

2 of 3
PER Pulse™ Recap

Community Practice Connections™: Advancing RCC: A Focused Assessment of Recent Paradigm Shifts and Next Steps to Move the Field Forward is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in February 2017 in Orlando, FL. In this online activity, expert faculty discuss standards of care and emerging strategies for renal cell carcinoma (RCC). It features commentary on:

  • Targeted therapy in the adjuvant and relapsed metastatic settings by Robert Figlin, MD
  • Immunotherapy for RCC in 2017 by David McDermott, MD
  • Informed therapeutic sequencing by Sumanta Pal, MD
  • Non‒clear cell RCC by Bernard Escudier, MD
  • A look ahead in RCC, by Toni Choueiri, MD

This second of 3 PER Pulse™ Recaps summarizing the online program focuses on Dr. Pal’s answers to questions about sequencing therapies for metastatic RCC, during which he discussed:

  • His approach toward a patient with poor-risk, metastatic RCC with multiple lung nodules and diffuse, painful bony metastases
  • His perspectives on use of bevacizumab or an mTOR inhibitor in the current therapeutic landscape
  • The portfolio of ongoing, front-line clinical trials in RCC, including studies comparing bevacizumab + atezolizumab versus sunitinib, axitinib + nivolumab versus sunitinib, and nivolumab + ipilimumab versus sunitinib.
  • Interesting results from a circulating tumor DNA analysis, presented at ASCO GU 2017, that may influence treatment selection and drug development in the future
  • Compelling data from a randomized phase II study of front-line bevacizumab + atezolizumab for patients with advanced RCC that suggested that this combination may preferentially benefit patients who are PD‒L1-positive

3 of 3
PER Pulse™ Recap

Community Practice Connections™: Advancing RCC: A Focused Assessment of Recent Paradigm Shifts and Next Steps to Move the Field Forward is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in February 2017 in Orlando, FL. In this online activity, expert faculty discuss standards of care and emerging strategies for renal cell carcinoma (RCC). It features commentary on:

  • Targeted therapy in the adjuvant and relapsed metastatic settings by Robert Figlin, MD
  • Immunotherapy for RCC in 2017 by David McDermott, MD
  • Informed therapeutic sequencing by Sumanta Pal, MD
  • Non‒clear cell RCC by Bernard Escudier, MD
  • A look ahead in RCC, by Toni Choueiri, MD

This third of 3 PER Pulse™ Recaps summarizing the online program focuses on Dr. McDermott’s answers to questions about immunotherapy in RCC, during which he discussed:

  • His approach toward a 66-year-old male with metastatic RCC who progressed while on sunitinib therapy, experienced gastrointestinal toxicity while on second-line nivolumab, and eventually developed asymptomatic progression while on nivolumab.
  • Circumstances where an endoscopy/colonoscopy would be appropriate for a patient experiencing immune-related gastrointestinal toxicity.
  • His approach toward educating patients about potential immune-related adverse events
  • The immune-related adverse events that he finds most challenging to manage
  • Practical guidance for community oncologists regarding monitoring for and managing adverse events (immune-related and TKI-related)






Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
  12345
6789101112
13141516171819
20212223242526
2728293031
Filter By